Trial Profile
Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Carboplatin; Cisplatin; Docetaxel; Gemcitabine; Paclitaxel; Pemetrexed; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 816
- Sponsors Bristol-Myers Squibb
- 01 Feb 2024 Results of efficacy and safety outcomes in the Japanese subpopulation, published in the Cancer Science
- 24 Oct 2023 Results of exploratory analyses assessing clinical efficacy outcome (3 year) of neoadjuvant nivolumab in patients with NSCLC, presented at the 48th European Society for Medical Oncology Congress.
- 24 Oct 2023 Results assessing exploratory analyses from the concurrently randomized N + I and C arms of the study presented at the 48th European Society for Medical Oncology Congress